BBIO: Strong growth and pipeline launches position the business for sustained expansion and innovation
The business is experiencing strong growth with Attruby and anticipates further acceleration from three major drug launches in 2027. Differentiation in ATTR-CM, robust pipeline data, and targeted launch strategies for rare diseases underpin confidence in sustained expansion and capital deployment f…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.